Breaking News

Parexel Expands Model-based Drug Development Offering

Looks to further help reduce risk along drug development continuum

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Parexel International Corporation, a global biopharmaceutical services provider, has expanded services and capabilities in model-based drug development (MBDD) through their Quantitative Clinical Development (QCD) group.  The Parexel QCD team also offers services in all strategic and quantitative aspects of clinical pharmacology for biopharmaceutical companies to help expedite drug development, minimize risk, and support regulatory approval processes. Leveraging mathematical models for a quant...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters